Understand the source comparison
SS-31 FAQ: Comparison of Mitochondrial-Targeting Research Compounds
Research teams evaluating SS-31 for specific protocols consistently ask how it compares to other mitochondrial-targeted compounds. Particularly MitoQ (mitoquinone), SkQ1 (plastoquinone derivative), and the broader CoQ10 family. The comparison matters because t
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Research teams evaluating SS-31 for specific protocols consistently ask how it compares to other mitochondrial-targeted compounds. Particularly MitoQ (mitoquinone), SkQ1 (plastoquinone derivative), and the broader CoQ10 family. The comparison matters because these compounds target overlapping pathways but use fundamentally different mechanisms to reach mitochondria.
- SS-31 (Elamipretide)
- Electrostatic attraction to inner membrane via alternating cationic charges
- Cardiolipin stabilization + direct ROS scavenging
- 0.5–10 mg/kg SC/IP daily
- Cost per mg; requires cold storage
- Best choice for cristae structure research; only compound proven to preserve cardiolipin in vivo
- MitoQ (Mitoquinone)
- TPP cation (triphenylphosphonium) conjugated to ubiquinone
- Electron donation to reduce existing ROS
- 5–50 mg/kg oral daily
- TPP toxicity at high doses; variable oral absorption
- Effective antioxidant but doesn't address cardiolipin; better for ROS reduction than structural protection
- SkQ1 (Plastoquinone)
- TPP cation conjugated to plastoquinone
- Lipid peroxidation prevention in membranes
- 1–10 nmol/kg oral/IP
- Limited availability; less studied than MitoQ
- Potent at very low doses; best lipid antioxidant but no cristae effect
- CoQ10 (Ubiquinone)
- Passive diffusion (lipophilic)
- Electron transport chain cofactor + antioxidant
- 50–200 mg/kg oral daily
- Poor bioavailability; doesn't selectively target mitochondria
- Useful for ETC support but unreliable mitochondrial delivery; requires weeks to show effect
- Idebenone
- Synthetic CoQ10 analog
- Electron transport chain bypass
- 30–100 mg/kg oral daily
- Does not cross blood-brain barrier well
- Better bioavailability than CoQ10 but still non-targeted delivery
- The critical distinction is mechanism specificity. SS-31 is the only compound in this table that directly stabilizes cardiolipin and preserves cristae architecture. MitoQ and SkQ1 reduce oxidative stress but don't prevent the structural membrane changes that collapse cristae and reduce ATP synthesis capacity. This matters intensely in disease models where mitochondrial morphology drives pathology. Heart failure research, for instance, shows that cristae disruption precedes observable cardiac dysfunction by weeks, making cardiolipin stabilization a potential preventive target that pure antioxidants cannot address. Research teams working on neurodegenerative models where synaptic mitochondria show cristae loss (Alzheimer's, Parkinson's) consistently report that SS-31 produces effects MitoQ does not, despite MitoQ showing superior ROS scavenging in isolated mitochondrial preparations. The structural component matters as much as the antioxidant component. Often more.